NeuroPace (NASDAQ:NPCE) Given New $22.00 Price Target at UBS Group

NeuroPace (NASDAQ:NPCE) had its price target upped by research analysts at UBS Group from $18.00 to $22.00 in a note issued to investors on Tuesday,Benzinga reports. The firm currently has a “buy” rating on the stock. UBS Group’s price target would indicate a potential upside of 37.80% from the company’s previous close.

Other research analysts also recently issued research reports about the stock. Cantor Fitzgerald restated an “overweight” rating and set a $16.00 price target on shares of NeuroPace in a report on Wednesday, November 5th. Wells Fargo & Company upped their price target on NeuroPace from $15.00 to $16.00 and gave the stock an “overweight” rating in a research note on Wednesday, November 5th. Leerink Partners restated an “outperform” rating and issued a $19.00 target price on shares of NeuroPace in a report on Wednesday, November 5th. JPMorgan Chase & Co. increased their price target on NeuroPace from $18.00 to $20.00 and gave the company an “overweight” rating in a report on Wednesday, December 10th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of NeuroPace in a report on Tuesday, December 9th. Six investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $18.50.

NeuroPace Stock Down 1.4%

NPCE stock opened at $15.97 on Tuesday. The company has a debt-to-equity ratio of 3.17, a current ratio of 4.86 and a quick ratio of 3.94. The firm has a market capitalization of $531.79 million, a P/E ratio of -20.86 and a beta of 1.84. NeuroPace has a 52-week low of $7.56 and a 52-week high of $18.98. The company’s 50 day simple moving average is $13.09 and its 200-day simple moving average is $11.11.

NeuroPace (NASDAQ:NPCE) last announced its earnings results on Tuesday, November 4th. The company reported ($0.11) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.20) by $0.09. The company had revenue of $27.35 million for the quarter, compared to the consensus estimate of $24.64 million. NeuroPace had a negative net margin of 25.28% and a negative return on equity of 136.60%. As a group, equities research analysts anticipate that NeuroPace will post -1 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Ameritas Investment Partners Inc. increased its holdings in NeuroPace by 83.6% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 2,455 shares of the company’s stock valued at $27,000 after buying an additional 1,118 shares during the period. Legal & General Group Plc lifted its stake in NeuroPace by 86.0% during the second quarter. Legal & General Group Plc now owns 2,679 shares of the company’s stock worth $30,000 after purchasing an additional 1,239 shares during the period. Quantbot Technologies LP acquired a new stake in NeuroPace during the second quarter valued at approximately $35,000. Quarry LP grew its stake in shares of NeuroPace by 94.9% in the 3rd quarter. Quarry LP now owns 3,845 shares of the company’s stock valued at $40,000 after purchasing an additional 1,872 shares during the period. Finally, Police & Firemen s Retirement System of New Jersey raised its holdings in shares of NeuroPace by 72.0% in the 2nd quarter. Police & Firemen s Retirement System of New Jersey now owns 6,371 shares of the company’s stock worth $71,000 after buying an additional 2,668 shares in the last quarter. 78.83% of the stock is owned by institutional investors.

NeuroPace Company Profile

NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.